ResMed Inc. (NYSE:RMD) Shares Purchased by Aviva PLC

Aviva PLC increased its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 658.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,305 shares of the medical equipment provider's stock after buying an additional 54,094 shares during the quarter. Aviva PLC's holdings in ResMed were worth $14,249,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in ResMed by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 18,173,462 shares of the medical equipment provider's stock worth $4,156,089,000 after acquiring an additional 160,590 shares in the last quarter. Geode Capital Management LLC raised its position in shares of ResMed by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider's stock valued at $899,860,000 after purchasing an additional 85,270 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of ResMed by 3.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 957,020 shares of the medical equipment provider's stock valued at $218,861,000 after buying an additional 32,973 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in ResMed by 60.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 668,908 shares of the medical equipment provider's stock worth $152,973,000 after buying an additional 250,746 shares during the period. Finally, Amundi increased its stake in ResMed by 4.2% in the 4th quarter. Amundi now owns 590,212 shares of the medical equipment provider's stock worth $139,386,000 after buying an additional 23,775 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Remove Ads

Insider Transactions at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $219.74, for a total value of $439,480.00. Following the completion of the sale, the director now directly owns 73,218 shares of the company's stock, valued at approximately $16,088,923.32. This represents a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $236.77, for a total value of $1,896,290.93. Following the sale, the chief executive officer now directly owns 455,472 shares of the company's stock, valued at $107,842,105.44. The trade was a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 49,013 shares of company stock valued at $11,298,816. 0.71% of the stock is currently owned by corporate insiders.

ResMed Trading Up 1.4 %

Shares of NYSE RMD traded up $3.04 during mid-day trading on Friday, reaching $213.59. 2,305,933 shares of the company's stock were exchanged, compared to its average volume of 1,024,231. The firm has a market capitalization of $31.37 billion, a price-to-earnings ratio of 25.22, a PEG ratio of 1.53 and a beta of 0.75. ResMed Inc. has a 52-week low of $172.19 and a 52-week high of $263.05. The company's 50-day moving average is $225.64 and its 200-day moving average is $235.39. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. Analysts expect that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th were paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.99%. The ex-dividend date was Thursday, February 13th. ResMed's payout ratio is presently 25.03%.

Analysts Set New Price Targets

RMD has been the topic of several recent analyst reports. Piper Sandler lifted their price objective on shares of ResMed from $252.00 to $260.00 and gave the company a "neutral" rating in a research report on Friday, January 31st. UBS Group upgraded shares of ResMed from a "hold" rating to a "strong-buy" rating in a research note on Friday, January 31st. JPMorgan Chase & Co. raised their price objective on ResMed from $270.00 to $286.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Morgan Stanley began coverage on ResMed in a research report on Wednesday, March 19th. They issued an "overweight" rating and a $280.00 target price on the stock. Finally, Needham & Company LLC reissued a "hold" rating on shares of ResMed in a research note on Friday, January 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $249.73.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.